Board of directors

Peter has an operative background from Pharmacia Biotech, Amersham and GE Healthcare. He was general manager for Separations Division 1999-2006, and from 2006-2011, general manager for GE’s Life Sciences business which was acquired by Danaher in 2020. From 2011, he has worked as an entrepreneur with different companies and board roles. He  is presently chairman in Färjsundet Industri AB and Sophion A/S, and a board member at Biotage AB and Grönsöö Säteri AB. 

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Kirsti has more than 30 years of experience from the life science and pharmaceutical industries. She has previously held leading and executive positions at AstraZeneca, Pfizer and Swedish Orphan Biovitrim (Sobi), and was managing director for Pfizer Health AB during 2011-2014. She has held previous board assignments at Pfizer Health AB, PiiA, SwedenBio, OxThera AB and Envirotainer Holding AB. Kirsti is the founder and chairman of Kirsti Gjellan AB and holds current board assignments at the Royal Institute of Technology (KTH) and Xbrane Biopharma AB. 

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Peter Nählstedt has more than 20 years of operational experience from leading positions in life science and industry. His experience includes CEO of Probi AB (publ), Director Europe Trelleborg Marine Systems and General Manager North America BioProcess at GE Healthcare. He has also worked as consultant and advisor and held roles in marketing, sales and strategy at Sigma-Aldrich and GE Healthcare. Today he works as CEO of SenzaGen AB (publ) and is chairman of the board at Supersynbiotics AB and holds board positions at Bio-Works and Optiome AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Jonas Ahlén has over twenty years of experience in international financial markets. He has served as an advisor to investment funds and as a board member of healthcare and technology businesses in Europe and the UK. He is the CEO and board member of AB Bonit Invest, a family-owned investment company with a strong focus on healthcare investments. He has a background in institutional asset management, most recently as CEO of Storebrand Asset Management in Sweden. He started his career in investment banking, including with JP Morgan in London. He is the owner and founder of Ahlen Enterprises AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Thomas Gür has more than 40 years of experience in the areas of communication, investor relations, media handling, and public relations. He has served as an advisor on international affairs and as a board member of both listed and unlisted companies. He is the Chairman of the Board of Tellusgruppen AB, owner and founder of Ölander & Gür AB, and Klasse AB. He served as the external CEO of Accelerator Nordic AB from 2013 to 2014. He has also had assignments as a political commentator on the editorial pages for SvD, Göteborgs Posten, Finanstidningen, and ÖstgötaCorren. He has served as a former UN officer and press secretary for the Supreme Commander of the Swedish Defence Forces and of the Ministry of Trade and Commerce.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.